Oxytocin ameliorates cardiac hypertrophy by inhibiting mitochondrial dysfunction and pyroptosis via AMPK/PGC-1α /TFAM pathway
Life Sciences · 2026-04 · 391 · 124281
DOI: 10.1016/j.lfs.2026.124281 ↗Kurz gefasst
Fachartikel in der Zeitschrift Life Sciences, 2026-04. Verfasst von Quan Wang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology, The First Affiliated Hospital of Kunming Medical University, Kunming, People's Republic of China. Hauptthemen laut MEDLINE: Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha, Cardiomegaly, Oxytocin, AMP-Activated Protein Kinases. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 62 Literaturangaben. Gefördert von: Kunming Medical University, National Natural Science Foundation of China.
Abstract (Originalsprache)
AIM: Oxytocin (OT) is increasingly recognized as a cardiovascular homeostatic regulator with anti-remodeling potential; however, the mitochondrial and innate immune mechanisms underlying its anti-hypertrophic action remain incompletely defined. We therefore investigated whether OT protects against pathological cardiac hypertrophy by preserving mitochondrial homeostasis and suppressing mitochondria-derived inflammatory signaling. MATERIALS AND METHODS: An isoproterenol (ISO)-induced rat model and ISO-stimulated H9c2 cardiomyocytes were used. Cardiac remodeling was assessed by echocardiography, histopathology, and transmission electron microscopy. Hypertrophic/fibrotic markers were quantified by RT-qPCR. Mitochondrial function, oxidative stress, and cytosolic mtDNA leakage were evaluated in vitro. The AMPK/PGC-1α/TFAM axis and the cGAS-STING-NLRP3 inflammasome pathway were interrogated by pharmacological inhibition and gene silencing to establish causality. KEY FINDINGS: OT significantly attenuated ISO-induced cardiac hypertrophy, fibrosis, and inflammatory injury in vivo, accompanied by improved mitochondrial ultrastructure, restored PGC-1α/TFAM signaling, and reduced pyroptosis-related protein expression. In H9c2 cells, OT activated AMPK, rescued PGC-1α/TFAM signaling, alleviated mitochondrial dysfunction and oxidative stress, limited cytosolic mtDNA leakage, and suppressed the cGAS-STING-NLRP3 pyroptosis cascade. Blockade of AMPK or PGC-1α, as well as TFAM knockdown, largely abrogated OT-mediated protection, whereas STING inhibition partially restored the anti-pyroptotic effects under TFAM-deficient conditions. SIGNIFICANCE: Oxytocin protects against pathological cardiac hypertrophy by preserving mitochondrial integrity and inhibiting oxidative stress- and cGAS-STING-NLRP3 inflammasome-mediated pyroptosis via the AMPK/PGC-1α/TFAM pathway, highlighting its potential as a therapeutic strategy for preventing maladaptive cardiac remodeling.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anesthesiology, The First Affiliated Hospital of Kunming Medical University, Kunming, People's Republic of China.
- Department of Anesthesiology, The First Affiliated Hospital of Kunming Medical University, Kunming, People's Republic of China. Electronic address: wangzhuoran@ydyy.cn.
- Department of Anesthesiology, The First Affiliated Hospital of Kunming Medical University, Kunming, People's Republic of China. Electronic address: yangyuqiao@ydyy.cn.
- Department of Anesthesiology, The First Affiliated Hospital of Kunming Medical University, Kunming, People's Republic of China. Electronic address: qianjinqiao@ydyy.cn.
Förderung
- Kunming Medical University
- National Natural Science Foundation of China
Zitieren
APA
Wang, Q., Qian, X., Zhao, Y., Wu, W., Liu, J., Fu, N., Wang, L., Qin, H., Wang, Z., Yang, Y., & Qian, J. (2026). Oxytocin ameliorates cardiac hypertrophy by inhibiting mitochondrial dysfunction and pyroptosis via AMPK/PGC-1α /TFAM pathway. Life Sciences, 391, 124281. https://doi.org/10.1016/j.lfs.2026.124281
Vancouver
Wang Q, Qian X, Zhao Y, Wu W, Liu J, Fu N, et al. Oxytocin ameliorates cardiac hypertrophy by inhibiting mitochondrial dysfunction and pyroptosis via AMPK/PGC-1α /TFAM pathway. Life Sciences. 2026;391:124281. doi:10.1016/j.lfs.2026.124281
BibTeX
@article{Wang2026,
author = {Wang, Quan and Qian, Xi and Zhao, Yu and Wu, Wen and Liu, Jin and Fu, Na and Wang, Lingyan and Qin, Haiyan and Wang, Zhuoran and Yang, Yuqiao and Qian, Jinqiao},
title = {Oxytocin ameliorates cardiac hypertrophy by inhibiting mitochondrial dysfunction and pyroptosis via AMPK/PGC-1α /TFAM pathway},
journal = {Life Sciences},
year = {2026},
volume = {391},
pages = {124281},
doi = {10.1016/j.lfs.2026.124281}
}
EUVIMED